Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-02-10

FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Supplemental Application (Par Health USA, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Lamotrigine Extended Release, authorizing its extended-release formulation from Par Health USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamotrigine Extended-Release (Lamotrigine extended-release)

Snippet

SUPPL AP for LAMOTRIGINE EXTENDED RELEASE (LAMOTRIGINE EXTENDED RELEASE)